52
|
Nabhan C, Lestingi TM, Galvez A, Tolzien K, Kelby SK, Tsarwhas D, Newman S, Bitran JD. Erlotinib has moderate single-agent activity in chemotherapy-naïve castration-resistant prostate cancer: final results of a phase II trial. Urology 2009; 74:665-71. [PMID: 19616281 DOI: 10.1016/j.urology.2009.05.016] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2009] [Revised: 05/05/2009] [Accepted: 05/07/2009] [Indexed: 11/30/2022]
Abstract
OBJECTIVES To investigate the efficacy and toxicity of single-agent erlotinib in chemotherapy-naive castration-resistant prostate cancer. METHODS Eligible patients received erlotinib at 150 mg daily until disease progression. Toxicity was assessed every 2 weeks and responses every 8 weeks. Primary end point was assessing the overall clinical benefit measured as the sum of stable disease, partial response, and complete response. Secondary end points included time to disease progression, overall survival, and toxicity using the National Cancer Institute Common Toxicity Criteria version 3.0. RESULTS A total of 29 patients were enrolled in this study. Median age was 77 and median prostate-specific antigen was 66.3 ng/mL. Of 22 evaluable patients, 2 met the criteria for partial response and 5 demonstrated stable disease for an overall clinical benefit of 31%. PSA-doubling time improved in all responding patients to a median of 6 months from 3 months before entry into the study. One patient remained in study at 28 months, and 2 had > 50% decrease in their serum PSA level. Median time to disease progression was 2 months, but at 12 months, 9% of patients were progression-free. Median overall survival was 16.3 months, with 1- and 2-year survival rates of 58% and 27%, respectively. Erlotinib was well tolerated, with only 2 patients requiring dose reductions. Adverse events were as expected with grade 3 or 4 diarrhea, fatigue, and rash occurring in 10%, 6%, and 6% of patients, respectively. CONCLUSIONS Erlotinib has moderate activity in chemotherapy-naive castration-resistant prostate cancer, with some patients showing biochemical response. Future studies investigating this agent in combination are warranted. (This trial was registered at http://NCI.gov, NCT00272038).
Collapse
Affiliation(s)
- Chadi Nabhan
- Division of Hematology and Oncology, Department of Medicine, Oncology Specialists, Lutheran General Hospital, Park Ridge, IL 60068, USA.
| | | | | | | | | | | | | | | |
Collapse
|
53
|
Ferris FD, Bruera E, Cherny N, Cummings C, Currow D, Dudgeon D, JanJan N, Strasser F, von Gunten CF, Von Roenn JH. Palliative Cancer Care a Decade Later: Accomplishments, the Need, Next Steps—From the American Society of Clinical Oncology. J Clin Oncol 2009; 27:3052-8. [PMID: 19451437 DOI: 10.1200/jco.2008.20.1558] [Citation(s) in RCA: 263] [Impact Index Per Article: 17.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Purpose In 1998, the American Society of Clinical Oncology (ASCO) published a special article regarding palliative care and companion recommendations. Herein we summarize the major accomplishments of ASCO regarding palliative cancer and highlight current needs and make recommendations to realize the Society's vision of comprehensive cancer care by 2020. Methods ASCO convened a task force of palliative care experts to assess the state of palliative cancer care in the Society's programs. We reviewed accomplishments, assessed current needs, and developed a definition of palliative cancer. Senior ASCO members and the Board of Directors reviewed and endorsed this article for submission to Journal of Clinical Oncology. Results Palliative cancer care is the integration into cancer care of therapies that address the multiple issues that cause suffering for patients and their families and impact their life quality. Effective provision of palliative cancer care requires an interdisciplinary team that can provide care in all patient settings, including outpatient clinics, acute and long-term care facilities, and private homes. Changes in current policy, drug availability, and education are necessary for the integration of palliative care throughout the experience of cancer, for the achievement of quality improvement initiatives, and for effective palliative cancer care research. Conclusion The need for palliative cancer care is greater than ever notwithstanding the strides made over the last decade. Further efforts are needed to realize the integration of palliative care in the model and vision of comprehensive cancer care by 2020.
Collapse
Affiliation(s)
- Frank D. Ferris
- From the San Diego Hospice and Palliative Care, San Diego, CA; M. D. Anderson Cancer Center, Houston, TX; Shaare Zedek Medical Center, Jerusalem, Israel; American Society of Clinical Oncology, Alexandria, VA; Flinders University, Adelaide, Australia; Queen's University, Kingston, Canada; Cantonal Hospital, St Gallen, Switzerland; and Northwestern University, Chicago, IL
| | - Eduardo Bruera
- From the San Diego Hospice and Palliative Care, San Diego, CA; M. D. Anderson Cancer Center, Houston, TX; Shaare Zedek Medical Center, Jerusalem, Israel; American Society of Clinical Oncology, Alexandria, VA; Flinders University, Adelaide, Australia; Queen's University, Kingston, Canada; Cantonal Hospital, St Gallen, Switzerland; and Northwestern University, Chicago, IL
| | - Nathan Cherny
- From the San Diego Hospice and Palliative Care, San Diego, CA; M. D. Anderson Cancer Center, Houston, TX; Shaare Zedek Medical Center, Jerusalem, Israel; American Society of Clinical Oncology, Alexandria, VA; Flinders University, Adelaide, Australia; Queen's University, Kingston, Canada; Cantonal Hospital, St Gallen, Switzerland; and Northwestern University, Chicago, IL
| | - Charmaine Cummings
- From the San Diego Hospice and Palliative Care, San Diego, CA; M. D. Anderson Cancer Center, Houston, TX; Shaare Zedek Medical Center, Jerusalem, Israel; American Society of Clinical Oncology, Alexandria, VA; Flinders University, Adelaide, Australia; Queen's University, Kingston, Canada; Cantonal Hospital, St Gallen, Switzerland; and Northwestern University, Chicago, IL
| | - David Currow
- From the San Diego Hospice and Palliative Care, San Diego, CA; M. D. Anderson Cancer Center, Houston, TX; Shaare Zedek Medical Center, Jerusalem, Israel; American Society of Clinical Oncology, Alexandria, VA; Flinders University, Adelaide, Australia; Queen's University, Kingston, Canada; Cantonal Hospital, St Gallen, Switzerland; and Northwestern University, Chicago, IL
| | - Deborah Dudgeon
- From the San Diego Hospice and Palliative Care, San Diego, CA; M. D. Anderson Cancer Center, Houston, TX; Shaare Zedek Medical Center, Jerusalem, Israel; American Society of Clinical Oncology, Alexandria, VA; Flinders University, Adelaide, Australia; Queen's University, Kingston, Canada; Cantonal Hospital, St Gallen, Switzerland; and Northwestern University, Chicago, IL
| | - Nora JanJan
- From the San Diego Hospice and Palliative Care, San Diego, CA; M. D. Anderson Cancer Center, Houston, TX; Shaare Zedek Medical Center, Jerusalem, Israel; American Society of Clinical Oncology, Alexandria, VA; Flinders University, Adelaide, Australia; Queen's University, Kingston, Canada; Cantonal Hospital, St Gallen, Switzerland; and Northwestern University, Chicago, IL
| | - Florian Strasser
- From the San Diego Hospice and Palliative Care, San Diego, CA; M. D. Anderson Cancer Center, Houston, TX; Shaare Zedek Medical Center, Jerusalem, Israel; American Society of Clinical Oncology, Alexandria, VA; Flinders University, Adelaide, Australia; Queen's University, Kingston, Canada; Cantonal Hospital, St Gallen, Switzerland; and Northwestern University, Chicago, IL
| | - Charles F. von Gunten
- From the San Diego Hospice and Palliative Care, San Diego, CA; M. D. Anderson Cancer Center, Houston, TX; Shaare Zedek Medical Center, Jerusalem, Israel; American Society of Clinical Oncology, Alexandria, VA; Flinders University, Adelaide, Australia; Queen's University, Kingston, Canada; Cantonal Hospital, St Gallen, Switzerland; and Northwestern University, Chicago, IL
| | - Jamie H. Von Roenn
- From the San Diego Hospice and Palliative Care, San Diego, CA; M. D. Anderson Cancer Center, Houston, TX; Shaare Zedek Medical Center, Jerusalem, Israel; American Society of Clinical Oncology, Alexandria, VA; Flinders University, Adelaide, Australia; Queen's University, Kingston, Canada; Cantonal Hospital, St Gallen, Switzerland; and Northwestern University, Chicago, IL
| |
Collapse
|
58
|
Suttmann H, Grgic A, Lehmann J, Zwergel U, Kamradt J, Gouverneur E, Pinkert J, Stöckle M, Kirsch CM, Nestle U. Combining 153Sm-Lexidronam and Docetaxel for the Treatment of Patients with Hormone-Refractory Prostate Cancer: First Experience. Cancer Biother Radiopharm 2008; 23:609-18. [DOI: 10.1089/cbr.2008.0487] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Henrik Suttmann
- Department of Urology and Pediatric Urology , Saarland University Medical Center, Homburg/Saar, Germany
| | - Aleksandar Grgic
- Department of Nuclear Medicine, Saarland University Medical Center, Homburg/Saar, Germany
| | - Jan Lehmann
- Department of Urology and Pediatric Urology , Saarland University Medical Center, Homburg/Saar, Germany
| | - Ulrike Zwergel
- Department of Urology and Pediatric Urology , Saarland University Medical Center, Homburg/Saar, Germany
| | - Jörn Kamradt
- Department of Urology and Pediatric Urology , Saarland University Medical Center, Homburg/Saar, Germany
| | - Eric Gouverneur
- Department of Nuclear Medicine, Saarland University Medical Center, Homburg/Saar, Germany
| | | | - Michael Stöckle
- Department of Urology and Pediatric Urology , Saarland University Medical Center, Homburg/Saar, Germany
| | - Carl-Martin Kirsch
- Department of Nuclear Medicine, Saarland University Medical Center, Homburg/Saar, Germany
| | - Ursula Nestle
- Department of Nuclear Medicine, Saarland University Medical Center, Homburg/Saar, Germany
| |
Collapse
|
59
|
Somerfield MR, Einhaus K, Hagerty KL, Brouwers MC, Seidenfeld J, Lyman GH. American Society of Clinical Oncology Clinical Practice Guidelines: Opportunities and Challenges. J Clin Oncol 2008; 26:4022-6. [DOI: 10.1200/jco.2008.17.7139] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The American Society of Clinical Oncology (ASCO) published its first clinical practice guideline, which focused on the use of hematopoietic colony-stimulating factors, in 1994. Since then, ASCO has published 24 additional guidelines or technology assessments on a range of topics and is developing 11 additional guidelines. Guidelines are among ASCO's most valued products, according to membership surveys and data from the JCO.org Web site. However, the same data from ASCO members have highlighted a number of limitations to the guideline program. These relate to the timelines of guideline updates, difficulties locating guidelines and related products, and challenges to implementing ASCO guidelines in everyday clinical practice. This article outlines the concrete steps that the ASCO Health Services Committee (HSC) is taking to address these limitations, including the institution of a more aggressive guideline updating schedule, a transition from narrative to systematic literature reviews to support the practice recommendations, a new Board of Directors–approved policy to permit endorsement of other groups’ guidelines, and a robust Clinical Tools and Resources program that offers a range of guideline dissemination and implementation aids. Additional work is underway to establish stronger and deeper collaborations with practicing oncologists to expand their role in the review, field testing, and implementation of guideline clinical tools and resources. Finally, the HSC is discussing evaluation of the guidelines program to maximize the impact of ASCO clinical practice guidelines on clinical decision making and, ultimately, the quality of cancer care.
Collapse
Affiliation(s)
- Mark R. Somerfield
- From the American Society of Clinical Oncology, Alexandria, VA; Duke University Medical Center, Durham, NC; and the Department of Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
| | - Kaitlin Einhaus
- From the American Society of Clinical Oncology, Alexandria, VA; Duke University Medical Center, Durham, NC; and the Department of Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
| | - Karen L. Hagerty
- From the American Society of Clinical Oncology, Alexandria, VA; Duke University Medical Center, Durham, NC; and the Department of Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
| | - Melissa C. Brouwers
- From the American Society of Clinical Oncology, Alexandria, VA; Duke University Medical Center, Durham, NC; and the Department of Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
| | - Jerome Seidenfeld
- From the American Society of Clinical Oncology, Alexandria, VA; Duke University Medical Center, Durham, NC; and the Department of Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
| | - Gary H. Lyman
- From the American Society of Clinical Oncology, Alexandria, VA; Duke University Medical Center, Durham, NC; and the Department of Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
| |
Collapse
|